Analisi costo-efficacia di due schemi adiuvanti per il trattamento del carcinoma del colon-retto: lettura dei dati dello studio mosaic

Tramarin A. , De Lalla F. : La farmacoeconomia degli inibitori delle proteasi: alcune considerazioni di natura metodologica. Incontri Aids, Genova, 1997.

Pagano E. , Garattini L. : I costi dell'AIDS: osservazioni dall'analisi della letteratura. In: AIDS 1998. Il contributo italiano. Dianzani F. , Ippolito G. , Moroni M. (a cura di). Piccin Nuova Libraria, Padova, 1998, 527–32.

Drummond M.F. , Stoddart G.L. , Torrance G.W. : Methods for the economic evaluation of health care programmes, 2nd ed. Oxford University Press, Oxford, 1997.

Rebesco B. , Amalfitano M.E. : Analisi farmacoeconomica di una struttura dipartimentale testacollo. In: Antibioticoterapia in otorinolaringoiatria. Pallestrini E.A. , Marcucci L. , Schito G. Forum Service, Genova, 2000.

Messori A. , et al. La Farmacoeconomia come disciplina scientifica: panoramica delle principali metodologie. Giornale di Farmacoeconomia, 2(8): 176–89, 1998.

Garattini L. , Grilli R. , Scopelliti D. , Mantovani L. : A proposal for Italian guidelines in pharmacoeconomics. PharmacoEconomics, 7(1): 1–6, 1995.

André T. , Boni C. , Mounedji-Boudiaf L. Oxaliplatin, fluorouracil and leucovorin as adjuvant treatment for colon cancer (MOSAIC). NEMJ, 350: 2343–2351, 2004.

Rebesco B. , Amalfitano M.E. , Cantagalli E. : Chemioterapici antiblastici: problematiche relative a Stabilità Allestimento Sicurezza. Mediprint Editore, 2003.

de Gramont A. , Figer A. , Seymour M. , et al: Leucovorin and fluorouracil with or without oxaliplatin as first line treatment of metastatic colorectal cancer. J Clin Oncol, 18: 2938–2947, 2000.

de Gramont A. , Bosset J.F. , Milan C. : Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer. J Clin Oncol, 15: 808–815, 1997.

Koperna T. , Semmler D. : Innovative chemotherapies for stage III colon cancer: cost effectiveness study. Hepatogastroenterology, 50(54): 1903–1909, 2003.

Douillard J. , Cunningham D. , Roth A. : Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355(9209); 1041–1047, 2000.

Sargent D.J. , Wiend S. , Benedetti J. : Disease-free survival (DFS) vs overall survival (OS) as a primary endpoint for adjuvant colon cancer studies: individual patient data from 12.915 patients on 15 randomized trials. Proc Am Soc Clin Oncol, 23: 245s (abstract 3502); 2004.

Messori A. , Trippoli S. , Vaiani M. : Price needs to be evaluated against effectiveness. BMJ, 325: 1302, 2002.

Garattini S. , Bertelè V. : Efficacy, safety, and cost of new anticancer drugs. BMJ, 325: 269–271; 2002.

de Gramont A. , Boni C. , Navarro M. : Oxaliplatin/5FU/LV in the adjuvant treatment of II e III stage colon cancer: efficacy results with a median follow-up of 4 years. Proc ASCO, abst 3501, 2005.

Sloan F.A. (ed): Valuing health care: costs, benefits and effectiveness of pharmaceutical and other medical technologies. Cambridge University Press, Cambridge, 1995.